These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 33359710)
1. The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism. Kanugovi Vijayavittal A; Amere Subbarao S Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118943. PubMed ID: 33359710 [TBL] [Abstract][Full Text] [Related]
2. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model. Nam S; Kim H; Hong D; Park JB; Kim SJ Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812 [TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138 [TBL] [Abstract][Full Text] [Related]
4. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Stravopodis DJ; Margaritis LH; Voutsinas GE Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746 [TBL] [Abstract][Full Text] [Related]
5. Induction of premature senescence by hsp90 inhibition in small cell lung cancer. Restall IJ; Lorimer IA PLoS One; 2010 Jun; 5(6):e11076. PubMed ID: 20552022 [TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 inhibition in lung cancer. Shimamura T; Shapiro GI J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S152-9. PubMed ID: 18520302 [TBL] [Abstract][Full Text] [Related]
7. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells. Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586 [TBL] [Abstract][Full Text] [Related]
8. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276 [TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model. Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284 [TBL] [Abstract][Full Text] [Related]
10. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells. Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113 [TBL] [Abstract][Full Text] [Related]
11. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615 [TBL] [Abstract][Full Text] [Related]
12. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556 [TBL] [Abstract][Full Text] [Related]
14. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565 [TBL] [Abstract][Full Text] [Related]
15. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665 [TBL] [Abstract][Full Text] [Related]
16. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415 [TBL] [Abstract][Full Text] [Related]
17. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293 [TBL] [Abstract][Full Text] [Related]
18. Geldanamycin and its anti-cancer activities. Fukuyo Y; Hunt CR; Horikoshi N Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405 [TBL] [Abstract][Full Text] [Related]
19. Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis. Wang Z; Hu Y; Xiao D; Wang J; Liu C; Xu Y; Shi X; Jiang P; Huang L; Li P; Liu H; Qing G Clin Cancer Res; 2017 Jul; 23(14):3834-3846. PubMed ID: 28143869 [No Abstract] [Full Text] [Related]